Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company currently focused on developing novel treatments for multiple myeloma, announced today that the abstracts for the 60th American Society of Hematology (ASH) Annual Meeting (December 1-4, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR).
Stockholm – November 1, 2018 –Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company currently focused on developing novel treatments for multiple myeloma, announced today that the abstracts for the 60th American Society of Hematology (ASH) Annual Meeting (December 1-4, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR).
“We are happy to announce that HORIZON has been selected for an oral presentation at ASH and very much look forward to presenting new data from our ongoing clinical trials in patients with relapsed/refractory multiple myeloma. This is a significant recognition of the progress we are making in the development of melflufen,” said Jakob Lindberg, CEO of Oncopeptides.
Details of the two melflufen abstracts from Oncopeptides that have been accepted for presentation at the ASH 2018 Annual Meeting are:
Title: HORIZON - Melflufen therapy for RRMM patients refractory to daratumumab and/or pomalidomide; updated results and clinical outcome
Presenter: Paul G. Richardson, MD, Professor of Medicine at Harvard Medical School and Clinical Program Leader, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute in Boston, Massachusetts, USA
Session: Oral Session, Myeloma: Therapy, excluding Transplantation: Antibodies and Targeted Therapies
Date/Time: Monday, December 3 at 8:15 a.m. PST
Location: Room 6F
Title: The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data
Presenter: Ludek Pour, MD, Fakultní nemocnice Brno, Brno, Czech Republic
Session: Poster Session, Myeloma: Therapy, excluding Transplantation
Date/Time: Saturday, December 1 at 6:15 p.m. PST
Location: Hall GH
The abstract data cut for ANCHOR was May 10, 2018, for HORIZON and July 18, 2018. However, further data will be presented at ASH with data cuts during October (HORIZON) and November (ANCHOR) when more patients have been treated for evaluation than what is available in the abstracts. Full abstracts can be downloaded at https://www.oncopeptides.se/en/ash-abstracs-2018/.
“Over the last 2 years, we have consistently generated good efficacy and tolerability data in RRMM patients on our path to establish melflufen as a new potential back-bone therapy after IMiDs and PIs in RRMM patients,” said Lindberg. “From the trial ANCHOR, we will for the first time show efficacy and tolerability data when treating RRMM patients with melflufen in combination with other myeloma drugs. Furthermore, we will present updated data from HORIZON where we treat very ill patients that have few or no remaining treatment options with melflufen.”
About the ANCHOR Study
ANCHOR is an ongoing Phase I / II study that will include up to 64 patients. It is an open, single-arm study, in which melflufen (Ygalo®) and dexamethasone (steroid) is administered in combination with bortezomib (cohort A) or daratumumab (cohort B) in RRMM patients. Melflufen is administred as either 20mg, 30mg or 40mg every 28 days.
About the HORIZON Study
HORIZON is an ongoing open single-armed phase II trial in which melflufen (Ygalo®) and dexamethasone (steroid) is used in RRMM patients with few or no remaining treatment options.
Media Contact
Christy Curran
Sam Brown, Inc.
christycurran@sambrown.com
615.414.8668
The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on November 1, 2018 at 14.00 (CET).
About Oncopeptides
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), an alkylating peptide, belonging to a new class of drugs (Peptidase Enhanced Compounds – PEnCs). Melflufen (Ygalo®) is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen (Ygalo®) compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen (Ygalo®) will potentially provide physicians with a new treatment option for patients suffering from this serious disease. Visit www.oncopeptides.com for more information.
